|
시장보고서
상품코드
2084692
간질성 폐질환 시장 : 질환 유형별, 약제 유형별, 유통 채널별, 지역별Interstitial Lung Disease Market, By Disease Type, By Drug Type, By Distribution Channel, By Geography |
||||||
간질성 폐질환 시장은 2026년에 45억 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 72억 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 6.8%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 45억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 6.80% | 2033년 시장 규모 예측 : | 72억 달러 |
간질성 폐질환(ILD)이란 폐에 흉터(섬유화)를 유발하는 일련의 질환을 가리키는 용어입니다. 이러한 흉터 형성으로 인해 폐가 딱딱해져 호흡이 어려워지고, 혈액으로의 산소 공급이 방해받게 됩니다. 간질성 폐질환은 석면 등의 유해 물질에 장기간 노출됨으로써 발생할 수 있습니다. 또한 류마티스 관절염과 같은 일부 자가면역 질환도 간질성 폐질환의 원인이 될 수 있습니다. 간질성 폐질환의 증상으로는 다음과 같은 것이 있습니다.
- 휴식시 호흡 곤란.
- 마른 기침.
간질성 폐질환으로 분류되는 질환에는 간질성 폐렴, 특발성 폐섬유증, 비특이성 간질성 폐렴, 과민성 폐렴, 원인 불명의 조직화 폐렴(COP), 사르코이드증, 그리고 급성 간질성 폐렴이 있습니다. 간질성 폐질환(ILD)은 코르티코스테로이드, 항섬유화제, 필페니돈, 닌테다닙 등의 약물로 치료할 수 있습니다.
시장 역학
규제 당국의 의약품 승인 건수 증가가 예측 기간 중 전 세계 간질성 폐질환 시장의 성장을 촉진할 것으로 예상됩니다. 예를 들어 2014년 10월, 미국 식품의약국(FDA)은 호흡 곤란을 유발하고 돌이킬 수 없는 폐 손상을 초래하는 진행성 치명적 폐 질환인 특발성 폐섬유증(IPF)의 치료제로 피르페니돈(Esbriet) 및 닌테다니브(Ofev)를 승인했습니다.
신약 출시 건수의 증가가 전 세계 간질성 폐질환 시장의 성장을 촉진할 것으로 예상됩니다. 예를 들어 2020년 10월, 연구 주도형 글로벌 통합 제약 기업인 글렌마크 파마슈티컬스는 인도에서 폐섬유증 치료제 '닌다니브(닌다니브 100mg 및 150mg 캡슐)'의 출시를 발표했습니다.
본 조사의 주요 특징
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신약 출시 및 승인, 지역별 전망, 그리고 주요 기업이 채택하고 있는 경쟁 전략에 관한 중요 인사이트도 제공하고 있습니다.
- 본 조사에서는 다음의 매개변수를 바탕으로 전 세계 간질성 폐질환 시장의 주요 기업 개요을 소개하고 있습니다. 구체적으로는 기업 개요, 재무 실적, 제품 포트폴리오, 사업 전개 지역, 유통 전략, 주요 발전 및 전략, 그리고 향후 계획입니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 기술 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 이 '세계의 간질성 폐질환 시장 보고서'는 투자자, 공급업체, 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 간질성 폐질환 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 개요
제3장 시장 역학·규제·동향 분석
제4장 세계의 간질성 폐질환 시장 : 질환 유형별, 2021-2033년
제5장 세계의 간질성 폐질환 시장 : 약제 유형별, 2021-2033년
제6장 세계의 간질성 폐질환 시장 : 유통 채널별, 2021-2033년
제7장 세계의 간질성 폐질환 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSA 26.07.14Interstitial Lung Disease Market is estimated to be valued at USD 4.5 Bn in 2026 and is expected to reach USD 7.20 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 4.5 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.80% | 2033 Value Projection: | USD 7.20 Bn |
Interstitial lung disease (ILD) is a term used for group of diseases that cause scarring (fibrosis) of the lungs. This scarring causes stiffness in the lungs, which makes difficult to breathe and supply oxygen to the bloodstream. Interstitial lung disease can be caused due to long-term exposure to hazardous materials such as asbestos. Some types of autoimmune diseases, such as rheumatoid arthritis, also can cause interstitial lung disease. The symptoms of interstitial lung disease include:
- Shortness of breath at rest
- Dry cough
The diseases which are grouped under interstitial lung disease are interstitial pneumonia, idiopathic pulmonary fibrosis, nonspecific interstitial pneumonitis, hypersensitivity pneumonitis, cryptogenic organizing pneumonia (COP), sarcoidosis, and acute interstitial pneumonitis. Interstitial lung disease (ILD) can be treated with medications such as corticosteroids, anti-fibrotic medication, Pirfenidone, and nintedanib.
Market Dynamics
Increasing number of drug approvals from regulatory bodies is expected to drive the growth of global interstitial lung disease market during the forecast period. For instance, in October 2014, the U.S. Food and Drug Administration (FDA) approved pirfenidone (Esbriet) and nintedanib (Ofev) for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease that makes breathing difficult and causes irreversible lung damage.
Increasing number of drug launches is expected to drive the growth of global interstitial lung disease market. For instance, in October 2020, Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, announced the launch of NINDANIB (Nintedanib 100 and 150 mg capsules) for the treatment of pulmonary fibrosis in India.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global interstitial lung disease market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
- Key companies covered as a part of this study include MSD (Merck), Liminal Biosciences, Glenmark Pharma, J.B. Chemicals & Pharmaceuticals, Boehringer Ingelhim International GmbH, F. Hoffmann-La Roche Ltd., and Cipla
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global interstitial lung disease market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the interstitial lung disease market.
Market Segmentation
- By Disease Type (Revenue, USD Bn, 2021-2033)
- Interstitial Pneumonia
- Idiopathic Pulmonary Fibrosis
- Nonspecific Interstitial Pneumonitis
- Hypersensitivity Pneumonitis
- Cryptogenic Organizing Pneumonia (COP)
- Sarcoidosis
- Acute Interstitial Pneumonitis
- By Drug Type (Revenue, USD Bn, 2021-2033)
- Corticosteroids
- Anti-fibrotic Medication
- Pirfenidone
- Nintedanib
- By Distribution Channel (Revenue, USD Bn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Interstitial Lung Disease Market, By Region (Revenue, USD Bn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- MSD (Merck)
- Liminal Biosciences
- Glenmark Pharma
- Chemicals & Pharmaceuticals
- Boehringer Ingelhim International GmbH
- Hoffmann-La Roche Ltd.
- Cipla
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Disease Type
- Market Snapshot, By Drug Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Disease Type Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Global Interstitial Lung Disease Market, By Disease Type, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Interstitial Pneumonia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Idiopathic Pulmonary Fibrosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Nonspecific Interstitial Pneumonitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Hypersensitivity Pneumonitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Cryptogenic Organizing Pneumonia (COP)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Sarcoidosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Acute Interstitial Pneumonitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
5. Global Interstitial Lung Disease Market, By Drug Type, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Anti-fibrotic Medication
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Pirfenidone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Nintedanib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
6. Global Interstitial Lung Disease Market, By Distribution Channel, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
7. Global Interstitial Lung Disease Market, By Region, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- MSD (Merck)
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Liminal Biosciences
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Glenmark Pharma
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- B. Chemicals & Pharmaceuticals
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Boehringer Ingelhim International GmbH
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- F. Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Cipla
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- MSD (Merck)
- Analyst Views
9. Section
- References
- Research Methodology
- About Us
